ISCO (International Stem Cell) Total Deposits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISCO International Stem Cell Corp ISCO
20 GF Score
Price $0.28
GF Value $0.13
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is International Stem Cell Total Deposits?

Total Deposits only applies to banks.

ISCO
20GF Score
International Stem Cell Corp ISCO
Total Deposits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.28 is trading 115.4% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • Total Deposits:
  • GF Value™: $0.13 vs. price of $0.28 (115.4% above fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp. is a clinical-stage biotechnology company based in the United States. It develops human parthenogenetic stem cells, derived from unfertilized eggs, and differentiates them into cell types for potential therapeutic use, including neural stem cells for Parkinson's disease and other central nervous system disorders, liver cells for congenital and acquired liver diseases, and retinal cells and three-dimensional eye structures. The company operates through three segments: therapeutic, biomedical, and anti-aging. Its biomedical segment generates most of its revenue and sells cell culture products, including stem cells, media, and reagents, to research institutions and life science customers. The anti-aging segment markets skincare products through its Lifeline Skin Care brand. The therapeutic segment remains in preclinical and clinical development, with revenue dependent on product sales from the biomedical and anti-aging businesses.
20GF Score

Get the complete analysis for ISCO

Total Deposits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$0.13
GF Value